The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.
 
Roberto Pili
Consulting or Advisory Role - Exelixis; Ipsen; Prometheus
Research Funding - Active Biotech; ARIAD; Millennium; Peregrine Pharmaceuticals; Pfizer; Syndax
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; US Biotest
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Costantine Albany
Stock and Other Ownership Interests - Advaxis
Honoraria - Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Seagen
Speakers' Bureau - Bayer; Sanofi
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Nabil Adra
Research Funding - Genentech (Inst); Merck (Inst)
 
Theodore F. Logan
Consulting or Advisory Role - Prometheus
Research Funding - Abbott Laboratories (Inst); Abraxis BioScience (Inst); Acceleron Pharma (Inst); Amgen (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BioVex (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Dynavax Technologies (Inst); Eisai (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche (Inst); Synta (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Andrew Greenspan
No Relationships to Disclose
 
Justin Budka
No Relationships to Disclose
 
Nur Damayanti
No Relationships to Disclose
 
Mark A Green
No Relationships to Disclose
 
James W. Fletcher
No Relationships to Disclose
 
Mark Tann
Research Funding - BTG (Inst)
 
Sara I Edwards
No Relationships to Disclose
 
Heather Burney
No Relationships to Disclose
 
Hao Liu
No Relationships to Disclose
 
Noah M. Hahn
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Health Advances; Inovio Pharmaceuticals; Merck; Oncogenex; Pieris Pharmaceuticals
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Principa Biopharma (Inst)